Lapatinib therapy for patients with advanced renal cell carcinoma

Nature Clinical Practice Oncology

Volumn 5, Issue 11, 2008, Pages 626-627

  Rini, Brian I ^a,b  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; MEGESTROL ACETATE; TAMOXIFEN;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY METASTASIS; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; RASH; SHORT SURVEY;

EID: 55549144316     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc1220     Document Type: Short Survey

References (9)

1. Rini BI and Small EJ (2005) Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 23: 1028-1043
2. Ravaud A et al. (2008) Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: A randomized phase III clinical trial. J Clin Oncol 26: 2285-2291
3. Bukowski RM et al. (2007) Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 25: 4536-4541
4. Motzer RJ et al. (2003) Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs 21: 99-101
5. Escudier B et al. (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125-134
6. Escudier B et al. (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 370: 2103-2111
7. Hudes G et al. (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271-2281
8. Motzer RJ et al. (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124
9. Motzer RJ et al. (2008) RAD001 vs placebo in patients with metastatic renal cell carcinoma (RCC) after progression on VEGFr-TKI therapy: Results from a randomized, double-blind, multicenter phase-III study. In Proceedings of the ASCO Annual Meeting: 2008 May 30-June 3; Chicago, IL, abstract #LBA5026